title: PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.
abstract: Among the emerging subunit vaccines are recombinant protein- and synthetic peptide-based vaccine formulations. However, proteins and peptides have a low intrinsic immunogenicity. A common strategy to overcome this is to co-deliver (an) antigen(s) with (an) immune modulator(s) by co-encapsulating them in a particulate delivery system, such as poly(lactic-co-glycolic acid) (PLGA) particles. Particulate PLGA formulations offer many advantages for antigen delivery as they are biocompatible and biodegradable; can protect the antigens from degradation and clearance; allow for co-encapsulation of antigens and immune modulators; can be targeted to antigen presenting cells; and their particulate nature can increase uptake and cross-presentation by mimicking the size and shape of an invading pathogen. In this review we discuss the pros and cons of using PLGA particulate formulations for subunit vaccine delivery and provide an overview of formulation parameters that influence their adjuvanticity and the ensuing immune response.
authors.affiliation: a Division of Drug Delivery Technology , Leiden Academic Center for Drug Research, Leiden University , Leiden , The Netherlands.
authors.forename: A L
authors.initials: AL
authors.lastname: Silva
authors.affiliation: b Intravacc (Institute for Translational Vaccinology) , Bilthoven , The Netherlands.
authors.forename: P C
authors.initials: PC
authors.lastname: Soema
authors.affiliation: a Division of Drug Delivery Technology , Leiden Academic Center for Drug Research, Leiden University , Leiden , The Netherlands.|c Cluster BioTherapeutics, Leiden Academic Center for Drug Research, Leiden University , Leiden , The Netherlands.
authors.forename: B
authors.initials: B
authors.lastname: Slütter
authors.affiliation: d Department of Immunohematology and Blood Transfusion , Leiden University Medical Center , Leiden , The Netherlands.
authors.forename: F
authors.initials: F
authors.lastname: Ossendorp
authors.affiliation: a Division of Drug Delivery Technology , Leiden Academic Center for Drug Research, Leiden University , Leiden , The Netherlands.
authors.forename: W
authors.initials: W
authors.lastname: Jiskoot
mesh_terms: D000941:Antigens / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D045142:Cross-Priming; D003713:Dendritic Cells / Q000276:immunology; D016503:Drug Delivery Systems; D006801:Humans; D007111:Immunity, Cellular; D000071497:Immunogenicity, Vaccine; D019344:Lactic Acid; D053758:Nanoparticles; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D022223:Vaccines, Subunit / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*
chemical_list: D000941:Antigens; D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid
keywords: PLGA; adjuvant; antigen; delivery systems; dendritic cells; microparticles; nanoparticles; subunit; vaccine